
Beta Drugs
Specialised in oncology, developing advanced products, scientific insights, and technical expertise across diverse applications.
Date | Investors | Amount | Round |
---|---|---|---|
N/A | €0.0 | round | |
* | $13.9m | Post IPO Equity | |
Total Funding | 000k |
Related Content
Beta Drugs Ltd. is a publicly traded pharmaceutical company specializing in the manufacturing and marketing of oncology and dermatology products. Founded in 2005 by Vijay Batra, the company is part of the Adley Group, which has roots in the pharmaceutical industry since 1985. Vijay Batra, a promoter with extensive experience, took over the company in 2014. Following his passing, his sons, Rahul Batra and Varun Batra, have taken the helm as Chairman & Managing Director and Joint Managing Director, respectively, continuing his legacy. Rahul Batra, a graduate of the University of Strathclyde, manages marketing and sales, while Varun Batra, who studied business in Toronto, oversees production and exports.
The company's core business revolves around developing, manufacturing, and selling a comprehensive portfolio of anti-cancer drugs. Its product range includes tablets, capsules, injections, and lyophilized (freeze-dried) injections, addressing various forms of cancer. The business model emphasizes providing affordable oncology medicines through strategies like in-house development of Active Pharmaceutical Ingredients (APIs) and formulations, which helps reduce costs. Beta Drugs primarily generates revenue from the sale of its products in India and also exports to other countries. Its client base includes major healthcare institutions such as Fortis Hospitals, Max Healthcare, and Sir H.N. Reliance Foundation Hospital.
Significant milestones for Beta Drugs include its incorporation in 2005, being taken over by promoter Vijay Batra in 2014, and setting up a state-of-the-art manufacturing facility for oncology formulations the same year. The company went public with an Initial Public Offering (IPO) on the NSE SME platform in October 2017. Subsequently, it established an oncology plant in Uzbekistan in 2018 and has received manufacturing approvals from international bodies like Brazil's ANVISA, opening gateways to markets in Latin America and beyond. The company has demonstrated strong financial performance, with consistent revenue and profit growth over the past several years.
Keywords: oncology pharmaceuticals, anti-cancer drugs, pharmaceutical manufacturing, generic oncology drugs, lyophilized injections, chemotherapy medications, Adley Group, Rahul Batra, Varun Batra, Indian pharmaceutical market, oncology APIs, contract development manufacturing organization (CDMO), dermatology products, pharmaceutical exports, public pharmaceutical company, cancer treatment, healthcare solutions, drug formulation, pharmaceutical research, GMP certified facility